Showing results (1381-1390 of 1,518) with videos related to
Sort By:
Pageof 152
Lung Cancer (Amsterdam, Netherlands)|August 8, 2025
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet studyRajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 StudyMichael Boyer, Mehmet A N Şendur, Delvys Rodríguez-Abreu, et al.JTO Clinical and Research Reports|February 16, 2023
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLCMarina C Garassino, Shirish Gadgeel, Silvia Novello, et al.Cancer Immunology, Immunotherapy : CII|June 14, 2021
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinomaJan Budczies, Martina Kirchner, Klaus Kluck, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trialGiorgio V Scagliotti, Maciej Krzakowski, Aleksandra Szczesna, et al.Lung Cancer (Amsterdam, Netherlands)|February 23, 2016
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapyMaurice Pérol, Tudor-Eliade Ciuleanu, Oscar Arrieta, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2025
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III TrialEnriqueta Felip, Nasser Altorki, Caicun Zhou, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 18, 2020
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and RecommendationsJordi Remon, Francesco Passiglia, Myung-Ju Ahn, et al.JTO Clinical and Research Reports|September 30, 2021
Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic <i>EGFR</i>-Mutated NSCLC: RELAY Japanese SubsetKazuto Nishio, Takashi Seto, Makoto Nishio, et al.Cell Reports|January 12, 2025
A conserved switch to less catalytically active Polycomb repressive complexes in non-dividing cellsRachel McCole, James Nolan, David M Reck, et al.Pageof 152